Deepika Malik MDFaculty, Department of Ophthalmology, Drexel University College of Medicine; Associate Professor, Department of Ophthalmology at Philadelphia College of Osteopathic Medicine; Vitreoretinal Surgery Associate at Moore Eye Institute, Philadelphia, PA
Deepika Malik, MD, is a highly experienced, fellowship-trained vitreoretinal surgeon with expertise in retinal detachments, macular disorders and retinal vein occlusions. She completed surgical vitreoretinal fellowship at Gavin Herbert Eye Institute at the University of California-Irvine, CA.
Dr Malik is Faculty, Department of Ophthalmology, Drexel University College of Medicine; Associate Professor, Department of Ophthalmology at Philadelphia College of osteopathic Medicine; and Vitreoretinal Surgery Associate at Moore eye Institute, Greater Philadelphia Area.
Dr. Malik is an accomplished researcher in extensive national clinic trials conducted to evaluate the efficacy of drugs and devices in the treatment of retinal disorders. Dr Malik has significant experience in teaching, publishing articles and journals on retinal diseases.
DisclosuresRelevant disclosures: Dr. Malik is an Advisory Board Member at Allergan. She also makes the following financial disclosures: financial disclosures: Allergan & Alimera Sciences.
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for nAMD
- Superior Outcomes With PPV With Scleral Buckle for Retinal Detachment With Inferior Retinal Breaks
- Phenotype and Outcomes of Phakic vs Pseudophakic Primary Rhegmatogenous Retinal Detachments
- Safety of Nurse-Led Dexamethasone Implant Service
- Deep Learning Algorithm for Assessing Diabetic Macular Edema
- Macular Hole Closure Without Endotamponade Application
- iOCT-Assisted Macular Hole Surgery
- Vision-Related Functioning in Patients Undergoing Pneumatic Retinopexy vs Vitrectomy for Primary Rhegmatogenous Retinal Detachment
- Key Practical Considerations in Using Approved Therapies for Exudative AMD
- An Overview of Agents for Exudative Age-Related Macular Degeneration